SA518391805B1 - صيغ صلبة لمركبات 5، 6-داي هيدرو-6-فينيل بنزو[إف] أيزوكينولين-2-أمين بها استبدال - Google Patents

صيغ صلبة لمركبات 5، 6-داي هيدرو-6-فينيل بنزو[إف] أيزوكينولين-2-أمين بها استبدال Download PDF

Info

Publication number
SA518391805B1
SA518391805B1 SA518391805A SA518391805A SA518391805B1 SA 518391805 B1 SA518391805 B1 SA 518391805B1 SA 518391805 A SA518391805 A SA 518391805A SA 518391805 A SA518391805 A SA 518391805A SA 518391805 B1 SA518391805 B1 SA 518391805B1
Authority
SA
Saudi Arabia
Prior art keywords
formula
approximately
models
compound
cancer
Prior art date
Application number
SA518391805A
Other languages
Arabic (ar)
English (en)
Inventor
بي ريد ديفيد
باتيس كريج
Original Assignee
اركول، انك
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by اركول، انك filed Critical اركول، انك
Publication of SA518391805B1 publication Critical patent/SA518391805B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SA518391805A 2015-12-17 2018-06-13 صيغ صلبة لمركبات 5، 6-داي هيدرو-6-فينيل بنزو[إف] أيزوكينولين-2-أمين بها استبدال SA518391805B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562268747P 2015-12-17 2015-12-17
PCT/US2016/067164 WO2017106642A1 (en) 2015-12-17 2016-12-16 Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds

Publications (1)

Publication Number Publication Date
SA518391805B1 true SA518391805B1 (ar) 2022-12-21

Family

ID=59057612

Family Applications (1)

Application Number Title Priority Date Filing Date
SA518391805A SA518391805B1 (ar) 2015-12-17 2018-06-13 صيغ صلبة لمركبات 5، 6-داي هيدرو-6-فينيل بنزو[إف] أيزوكينولين-2-أمين بها استبدال

Country Status (19)

Country Link
US (3) US9981921B2 (cg-RX-API-DMAC7.html)
EP (2) EP3390369B1 (cg-RX-API-DMAC7.html)
JP (2) JP2018537499A (cg-RX-API-DMAC7.html)
KR (1) KR20180086508A (cg-RX-API-DMAC7.html)
CN (1) CN108368061A (cg-RX-API-DMAC7.html)
AU (2) AU2016369523B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018012095A2 (cg-RX-API-DMAC7.html)
CA (1) CA3006081A1 (cg-RX-API-DMAC7.html)
EA (2) EA202091691A1 (cg-RX-API-DMAC7.html)
ES (1) ES2935818T3 (cg-RX-API-DMAC7.html)
HK (1) HK1256825A1 (cg-RX-API-DMAC7.html)
IL (1) IL259556B2 (cg-RX-API-DMAC7.html)
MX (2) MX385671B (cg-RX-API-DMAC7.html)
NZ (1) NZ742695A (cg-RX-API-DMAC7.html)
PH (2) PH12018501246A1 (cg-RX-API-DMAC7.html)
SA (1) SA518391805B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201804670PA (cg-RX-API-DMAC7.html)
TW (2) TWI796250B (cg-RX-API-DMAC7.html)
WO (1) WO2017106642A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106642A1 (en) * 2015-12-17 2017-06-22 Arqule, Inc. Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
MX2020012771A (es) 2015-12-17 2022-10-04 Arqule Inc Metodos para preparar 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-ami na sustituida.
WO2022053708A1 (en) 2020-09-14 2022-03-17 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of gastric adenocarcinoma
JP7641247B2 (ja) 2022-03-02 2025-03-06 日立建機株式会社 機械の性能診断装置

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU5330698A (en) * 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
EP1790634A3 (en) * 2003-06-18 2007-06-13 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal form and processes for preparing it
CA2710051C (en) * 2006-12-29 2017-05-16 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as axl inhibitors
CN102325755B (zh) * 2008-12-30 2015-07-01 艾科尔公司 取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物
JP5808818B2 (ja) * 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
WO2012177852A1 (en) 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
US9802954B2 (en) * 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
WO2013044816A1 (en) * 2011-09-30 2013-04-04 Sunshine Lake Pharma Co., Ltd. Crystalline forms of azilsartan and preparation and uses thereof
WO2017106642A1 (en) * 2015-12-17 2017-06-22 Arqule, Inc. Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
MX2020012771A (es) * 2015-12-17 2022-10-04 Arqule Inc Metodos para preparar 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-ami na sustituida.
US9847831B2 (en) 2016-04-08 2017-12-19 Ciena Corporation Dual wavelenth optical time domain reflectometer systems and methods embedded in a WDM system

Also Published As

Publication number Publication date
AU2022201947A1 (en) 2022-04-14
US20200002293A1 (en) 2020-01-02
MX2018007414A (es) 2018-11-09
MX385671B (es) 2025-03-18
SG11201804670PA (en) 2018-07-30
CA3006081A1 (en) 2017-06-22
MX2021000432A (es) 2022-07-28
IL259556B2 (en) 2023-09-01
EP3390369A4 (en) 2019-08-14
TW202241854A (zh) 2022-11-01
BR112018012095A2 (pt) 2018-11-27
AU2016369523A1 (en) 2018-06-07
EA036295B1 (ru) 2020-10-22
EP4019499A1 (en) 2022-06-29
JP2022031797A (ja) 2022-02-22
IL259556A (en) 2018-07-31
EA201891430A1 (ru) 2018-11-30
TWI796250B (zh) 2023-03-11
NZ742695A (en) 2022-10-28
US10717710B2 (en) 2020-07-21
US9981921B2 (en) 2018-05-29
PH12020551465A1 (en) 2021-07-26
US10227311B2 (en) 2019-03-12
AU2022201947B2 (en) 2023-07-27
US20170174636A1 (en) 2017-06-22
PH12018501246A1 (en) 2019-02-04
MX394320B (es) 2025-03-24
JP2018537499A (ja) 2018-12-20
TWI771280B (zh) 2022-07-21
TW201736352A (zh) 2017-10-16
EP3390369B1 (en) 2022-11-02
EP3390369A1 (en) 2018-10-24
WO2017106642A1 (en) 2017-06-22
HK1256825A1 (zh) 2019-10-04
EA202091691A1 (ru) 2021-01-29
IL259556B1 (en) 2023-05-01
AU2016369523B2 (en) 2021-12-23
US20180258055A1 (en) 2018-09-13
KR20180086508A (ko) 2018-07-31
CN108368061A (zh) 2018-08-03
ES2935818T3 (es) 2023-03-10

Similar Documents

Publication Publication Date Title
CN107548394B (zh) 调节激酶的化合物的固体形式
TW515794B (en) 2-oxoquinoline compounds and pharmaceutical use thereof
JP6418622B2 (ja) 2−(2,4,5−置換アニリン)ピリミジン誘導体、その薬物組成物及びその用途
JP2022517396A (ja) Egfr阻害剤の塩、結晶形及びその製造方法
CN104284584B (zh) 表皮生长因子受体激酶抑制剂的盐
BR112018004175B1 (pt) Composto pirazolo[3,4-d]pirimidina, composição farmacêutica, inibidor de her2 e agente antitumor contendo o dito composto e usos terapêuticos do dito composto
BR112019012263A2 (pt) composições e métodos para tratar câncer
ES2971448T3 (es) Composición farmacéutica para el tratamiento de tumores
KR20090108086A (ko) 췌장암 치료용 조성물
BR112014025508B1 (pt) forma de sal de um inibidor de histona metiltransferase ezh2 humana
BR112013000980B1 (pt) Composições farmacêuticas moduladoras de c-met
JP2021517902A (ja) 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用
TW201904957A (zh) 胺基嘧啶類化合物及其製備方法和用途
UA127760C2 (uk) Кристалічна тверда форма солі n-{4-[(6,7-диметоксихінолін-4-іл)окси]феніл}-n'-(4-фторфеніл)циклопропан-1,1-дикарбоксаміду (варіанти), спосіб отримання та метод використання
EP3929182A1 (en) Multi-target kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
US20220315576A1 (en) Polymorph of cdk9 inhibitor and preparation method for polymorph and use thereof
JP2022031797A (ja) 置換5,6-ジヒドロ-6-フェニルベンゾ[f]イソキノリン-2-アミン化合物の固体形態
US10323044B2 (en) Crystal of imidazo-oxazine, pharmaceutical composition containing said crystal, and method for producing said crystal
Dong et al. Design and synthesis of cantharidin derivative DCZ5418 as a TRIP13 inhibitor with anti-multiple myeloma activity in vitro and in vivo
ES3059167T3 (en) Crystalline forms of quinazoline derivatives, preparation, composition and use thereof
US20240317762A1 (en) Phthalazinone-based parp-1 inhibitors
CN109843868A (zh) Olig2活性的抑制
CN105566314B (zh) 一种盐酸替扎尼定化合物
TWI702210B (zh) 環狀胺衍生物之結晶及其醫藥用途
TW201840568A (zh) 使用吡唑并[3,4-d]嘧啶化合物之抗腫瘤效果增強劑